Overcoming Multidrug Resistance in Cancer Stem Cells

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Moitra, Karobi ^a  

^a Trinity Washington University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B5; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CURCUMIN; CYCLOSPORIN; DOXORUBICIN; MICRORNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; NESTIN; TARIQUIDAR; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ALLOSTERISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; STEM CELL; TRANSCRIPTION REGULATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; MOUSE; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; NEOPLASTIC PROCESSES; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84948753065     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/635745     Document Type: Review

References (49)

1. M. M. Gottesman, "Mechanisms of cancer drug resistance," Annual Review of Medicine, vol. 53, pp. 615-627, 2002.
2. M. D. Hall, M.D. Handley, and M. M. Gottesman, "Is resistance useless? Multidrug resistance and collateral sensitivity," Trends in Pharmacological Sciences, vol. 30, no. 10, pp. 546-556, 2009.
3. K. Moitra, H. Lou, and M. Dean, "Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development," Clinical Pharmacology and Therapeutics, vol. 89, no. 4, pp. 491-502, 2011.
4. M. Shackleton, "Normal stemcells and cancer stem cells: similar and different," Seminars in Cancer Biology, vol. 20, no. 2, pp. 85-92, 2010.
5. N. A. Lobo, Y. Shimono, D. Qian, and M.F. Clarke, "The biology of cancer stem cells," Annual Review of Cell and Developmental Biology, vol. 23, pp. 675-699, 2007.
6. M. Dean, The Human ATP-Binding Cassette (ABC) Transporter Superfamily, National Center for Biotechnology Information, Bethesda, Md, USA, 2002, http://www.ncbi.nlm.nih.gov/books/NBK3/.
7. C. W. Scharenberg, M. A. Harkey, and B. Torok-Storb, "The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors," Blood, vol. 99, no. 2, pp. 507-512, 2002.
8. A. H. Schinkel, J. J.M. Smit, O. van Tellingen et al., "Disruption of themouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs," Cell, vol. 77, no. 4, pp. 491-502, 1994.
9. L. Tang, S. M. Bergevoet, C. Gilissen et al., "Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells," BMC Pharmacology, vol. 10, article 12, 2010.
10. S. M. Graham, H. G. Jørgensen, E. Allan et al., "Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro," Blood, vol. 99, no. 1, pp. 319-325, 2002.
11. C. Hirschmann-Jax, A. E. Foster, G. G. Wulf et al., "A distinct 'side population' of cells with high drug efflux capacity in human tumor cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 39, pp. 14228-14233, 2004.
12. Y. Welte, J. Adjaye, H. R. Lehrach, and C. R. A. Regenbrecht, "Cancer stem cells in solid tumors: elusive or illusive?" Cell Communication and Signaling, vol. 8, article 6, 2010.
13. M. Dean, T. Fojo, and S. Bates, "Tumour stem cells and drug resistance," Nature Reviews Cancer, vol. 5, no. 4, pp. 275-284, 2005.
14. J. Zhou, C.-Y. Wang, T. Liu et al., "Persistence of side population cells with high drug efflux capacity in pancreatic cancer," World Journal of Gastroenterology, vol. 14, no. 6, pp. 925-930, 2008.
15. C.-P. Wu, A. M. Calcagno, and S. V. Ambudkar, "Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies," Current Molecular Pharmacology, vol. 1, no. 2, pp. 93-105, 2008.
16. J. A. Ludwig, G. Szakács, S. E. Martin et al., "Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer," Cancer Research, vol. 66, no. 9, pp. 4808-4815, 2006.
17. C.-P. Wu, S. Shukla, A. M. Calcagno, M. D. Hall, M. M. Gottesman, and S. V. Ambudkar, "Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of themultidrug resistance linked ABCG2 transporter," Molecular Cancer Therapeutics, vol. 6, no. 12, pp. 3287-3296, 2007.
18. M. H. G. P. Raaijmakers, E. P. L. M. de Grouw, B. A. van der Reijden, T. J. M. de Witte, J. H. Jansen, and R. A. P. Raymakers, "ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acutemyelogenous leukemia," Clinical Cancer Research, vol. 12, no. 11 I, pp. 3452-3458, 2006.
19. D. Mandal, K. Moitra, D. Ghosh, D. Xia, and S. Dey, "Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein," Biochemistry, vol. 51, no. 13, pp. 2852-2866, 2012.
20. S. Dey, M. Ramachandra, I. Pastan, M. M. Gottesman, and S. V. Ambudkar, "Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 20, pp. 10594-10599, 1997.
21. C. Pascaud, M. Garrigos, and S. Orlowski, "Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents," Biochemical Journal, vol. 333, no. 2, pp. 351-358, 1998.
22. C. Martin, G. Berridge, C. F. Higgins, P. Mistry, P. Charlton, and R. Callaghan, "Communication betweenmultiple drug binding sites on P-glycoprotein," Molecular Pharmacology, vol. 58, no. 3, pp. 624-632, 2000.
23. N. Maki, P. Hafkemeyer, and S. Dey, "Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation," The Journal of Biological Chemistry, vol. 278, no. 20, pp. 18132-18139, 2003.
24. Q. Yin, J. Shen, Z. Zhang, H. Yu, and Y. Li, "Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor," Advanced Drug Delivery Reviews, vol. 65, no. 13-14, pp. 1699-1715, 2013.
25. S. Moghassemi and A. Hadjizadeh, "Nano-niosomes as nanoscale drug delivery systems: an illustrated review," Journal of Controlled Release, vol. 185, no. 1, pp. 22-36, 2014.
26. L. Guo, H. Zhang, F. Wang et al., "Targetedmultidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system," International Journal of Nanomedicine, vol. 10, pp. 4535-4547, 2015.
27. A. Bernardi, E. Braganhol, E. Jäger et al., "Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model," Cancer Letters, vol. 281, no. 1, pp. 53-63, 2009.
28. Y. Patil, T. Sadhukha, L. Ma, and J. Panyam, "Nanoparticlemediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance," Journal of Controlled Release, vol. 136, no. 1, pp. 21-29, 2009.
29. M. Das and S. K. Sahoo, "Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance," PLoS ONE, vol. 7, no. 3, Article ID e32920, 2012.
30. C. F. Higgins and M. M. Gottesman, "Is the multidrug transporter a flippase?" Trends in Biochemical Sciences, vol. 17, no. 1, pp. 18-21, 1992.
31. M. D. Chavanpatil, Y. Patil, and J. Panyam, "Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoproteinmediated drug efflux," International Journal of Pharmaceutics, vol. 320, no. 1-2, pp. 150-156, 2006.
32. M.D. Chavanpatil, A. Khdair, B. Gerard et al., "Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux," Molecular Pharmaceutics, vol. 4, no. 5, pp. 730-738, 2007.
33. W. Rao, H. Wang, J. Han et al., "Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells," ACS Nano, vol. 9, no. 6, pp. 5725-5740, 2015.
34. K.W. Scotto and R.A. Johnson, "Transcription of themultidrug resistance geneMDR1: a therapeutic target," Molecular Interventions, vol. 1, no. 2, pp. 117-125, 2001.
35. K.-V. Chin, K. Ueda, I. Pastan, and M. M. Gottesman, "Modulation of activity of the promoter of the human MDR1 gene by Ras and p53," Science, vol. 255, no. 5043, pp. 459-462, 1992.
36. R. A. Johnson, E. M. Shepard, and K. W. Scotto, "Differential regulation of MDR1 transcription by the p53 family members: role of the DNA binding domain," The Journal of Biological Chemistry, vol. 280, no. 14, pp. 13213-13219, 2005.
37. W. Jin, K.W. Scotto, W. N. Hait, and J.-M. Yang, "Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells," Biochemical Pharmacology, vol. 74, no. 6, pp. 851-859, 2007.
38. J. T. Desano and L. Xu, "MicroRNA regulation of cancer stem cells and therapeutic implications," The AAPS Journal, vol. 11, no. 4, pp. 682-692, 2009.
39. O. Kovalchuk, J. Filkowski, J. Meservy et al., "Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin," Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 2152-2159, 2008.
40. H. Zhu, H. Wu, X. Liu et al., "Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells," Biochemical Pharmacology, vol. 76, no. 5, pp. 582-588, 2008.
41. E. Turrini, S. Haenisch, S. Laechelt, T. Diewock, O. Bruhn, and I. Cascorbi, "MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression," Pharmacogenetics and Genomics, vol. 22, pp. 198-205, 2012.
42. K. Moitra, K. Im, K. Limpert et al., "Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines," PLoS ONE, vol. 7, no. 9, Article IDe45268, 2012.
43. Z. Liang, H. Wu, J. Xia et al., "Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1," Biochemical Pharmacology, vol. 79, no. 6, pp. 817-824, 2010.
44. L. Zinzi, M. Contino, M. Cantore, E. Capparelli, M. Leopoldo, and N. A. Colabufo, "ABC transporters in CSCs membranes as a novel target for treating tumor relapse," Frontiers in Pharmacology, vol. 5, article 163, 2014.
45. H. Sasaki, Y. Nishizaki, C.-C. Hui, M. Nakafuku, and H. Kondoh, "Regulation of Gli2 and Gli3 activities by an aminoterminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling," Development, vol. 126, no. 17, pp. 3915-3924, 1999.
46. J. Sims-Mourtada, J. G. Izzo, J. Ajani, and K. S. C. Chao, "Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport," Oncogene, vol. 26, no. 38, pp. 5674-5679, 2007.
47. J. R. Remsberg, H. Lou, S. G. Tarasov, M. Dean, and N. I. Tarasova, "Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth," Journal of Medicinal Chemistry, vol. 50, no. 18, pp. 4534-4538, 2007.
48. M. Mimeault and S. K. Batra, "Recent progress on tissueresident adult stem cell biology and their therapeutic implications," Stem Cell Reviews, vol. 4, no. 1, pp. 27-49, 2008.
49. Y. Chen, M. M. Bieber, and N. N. H. Teng, "Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer," Molecular Carcinogenesis, vol. 53, no. 8, pp. 625-634, 2014.